Keywords
How to Cite
Abstract
The questions of duration and safety for treatment of osteoporosis with bisphosphonates are among the most important in the medical practice. Today, the issues of efficiency are raised, as well as what categories of patients bisphosphonate therapy is indicated for, how long the drugs of this group could be used, and is it possible to suspend the bisphosphonates temporally without increasing the risk of fractures. The article presents the new data on the possibility and the need for treatment interruptions of anti-osteoporotic drugs, so-called «drug holidays», without the loss of efficacy and the increased risk of fractures. The concept of «drug holidays» provides for the temporary suspension of active treatment with bisphosphonates in the safe period. It is believed that in this period
the anti-resorptive effect of the drugs is preserved, so it is safe. The selection of candidates for the interruption in the treatment and the monitoring features during «holidays» should be adapted to individual patients.
References
2. Black D.M. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON–Pivotal Fracture Trial (PFT) / D.M. Black, I.R. Reid, S. Boonen et al. // J. Bone Miner. Res. — 2012. — Vol. 27, № 2. — P. 243-254.
3. Black D.M. Continuing bisphosphonate treatment for osteoporosis — for whom and for how long? / D.M. Black, D.C. Bauer, A.V. Schwartz et al. // N. Engl.
J. Med. — 2012. — Vol. 366. — 2051-2053.
4. Bone H. Ten years’ experience with alendronate for osteoporosis in postmenopausal women / H. Bone, D. Hosking, J. Devogelaer et al. // N. Engl. J. Med. —
2004. — Vol. 350. — P. 1189-1199.
5. Brown J.P. Bisphosphonates for treatment of osteoporosis. Expected benefits, potential harms, and drug holidays / J.P. Brown, S. Morin, W. Leslie et al. //
Canadian Family Physician. — 2014. — Vol. 60. — P. 324-333.
6. Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw / J. Compston // Osteoporos Int. — 2011. — Vol. 22 (12). — P. 2951-2961.
7. Compston J., Bilezikian J. Bisphosphonate therapy for osteoporosis: The long and short of it / J. Compston, J. Bilezikian // J. Bone Miner. Res. — 2012. — Vol. 27. — P. 240-242.
8. Dell R. A retrospective analysis of all atypical femur fractures seen in a large California HMO from the years 2007 to 2009 [abstract] / R. Dell, D. Greene, S.M. Ott, S. Silverman, E. Eisemon, T. Funahashi et al. // J. Bone Miner. Res. — 2010. — Vol. 25. — Astr. 12886-D.
9. Diab D.L., Watts N.B. Bisphosphonate drug holiday: who, when and how long / D.L. Diab, N.B. Watts // Ther. Adv. Musculoskelet. Dis. — 2013. — Vol. 5 (3). — P. 107-111.
10. Ioannidis G. Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study / G. Ioannidis, A. Papaioannou, W.M. Hopman, N. Akhtar-Danesh, T. Anastassiades et al. // CMAJ. — 2009. — Vol. 181 (5). — P. 265-271.
11. Kanis J.A. Оn behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health–care level. Technical Report / J.A. Kanis // World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK. 2007: Printed by University of Sheffield.
12. Khan A.A., Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons / A.A. Khan, L.P. Rios, G.K. Sandor,
N. Khan, E. Peters, M.O. Rahman et al. // J. Rheumatol. — 2011. — Vol. 38 (7). — P. 1396-1402.
13. Looker A.C. Clinical use of biochemical markers of bone remodeling: current status and future directions / A.C. Looker, D.C. Bauer, C.H. Chesnut 3rd et al. //
Osteoporos Int. — 2000. — Vol. 11. — P. 467-480.
14. McClung M. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday / M. McClung, S.T. Harris, P.D. Miller et al. // Am. J. Med. — 2013. —
Vol. 126. — P. 13-20.
15. Nancollas G.H. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite / G.H. Nancollas, R. Tang, R.J. Phipps
et al. // Bone. — 2006. — Vol. 38. — P. 617-627.